FindTrial
Sign In

Detection bias in open-label trials of cancer drug: a meta-epidemiologic study

Detection bias in open-label trials of cancer drug: a meta-epidemiologic study - Detection bias in open-label trials of cancer drug: a meta-epidemiologic study

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000044623
Enrollment
Unknown
Registered
2021-06-22
Start date
2021-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-label trials of cancer drug assessed by both blinded and nonblinded adjudicators.

Interventions

None listed

Sponsors

Department of Health Promotion and Human Behavior, Kyoto University School of Public Health
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Randomized, controlled, open-label, parallel-group superiority trials investigating the efficacy of anticancer agents. Included cancers are focused on breast, lung, colorectal, prostate, stomach and kidney cancers.

Exclusion criteria

Exclusion criteria: Blinded, non-inferiority, equivalence, and single-arm trials.

Design outcomes

Primary

MeasureTime frame
Ratio of hazard ratio (RHR: HRnonblinded by HRblinded) of progression free survival (PFS)—

Secondary

MeasureTime frame
Ratio of odds ratio (ROR: ORnonblinded by ORblinded) of objective response ratio (ORR)—

Countries

Japan,Asia(except Japan),North America,South America,Australia,Europe,Africa

Contacts

Public ContactSatoshi Funada

Kyoto University Department of Health Promotion and Human Behavior, Kyoto University School of Public Health

sfunada@kuhp.kyoto-u.ac.jp075-753-9492

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026